A Phase 3 Trial of the Androgen Receptor Ligand-directed Degrader BMS-986365 Versus Investigator’s Choice in Patients with Metastatic Castration-resistant Prostate Cancer (CA071-1000 – rechARge)

A Phase 3 Trial of the Androgen Receptor Ligand-directed Degrader BMS-986365 Versus Investigator’s Choice in Patients with Metastatic Castration-resistant Prostate Cancer (CA071-1000 – rechARge)

Sunday, May 17, 2026 1:00 PM to 1:08 PM · 7 min. (America/New_York)
Hall B, The Square, Learning Lab
Detail
Oncology: Prostate

Log in

See all the content and easy-to-use features by logging in or registering!